RBSH
Rebus Holdings, Inc. focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. The company was founded in 2003 and is based in Westlake Village, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2023 Q2 | 0.00 | $0 | $156,000 |
| 2023 Q1 | -0.01 | $0 | -$424,000 |
| 2022 Q4 | 0.04 | $0 | -$129,000 |
| 2022 Q3 | 0.00 | $0 | -$131,000 |
| 2022 Q2 | -0.04 | $0 | -$322,000 |
| 2022 Q1 | -0.02 | $0 | -$124,000 |
| 2021 Q4 | 0.02 | $0 | -$284,000 |
| 2021 Q3 | 0.81 | $0 | -$135,000 |